Ligand Pharmaceuticals acquires monoclonal antibody maker OMT for $178M
This acquisition is a logical fit for Ligand, as OMT will add a slew of monoclonal antibody therapeutics to its small molecule-dominant pipeline.
OMT Inc.
This acquisition is a logical fit for Ligand, as OMT will add a slew of monoclonal antibody therapeutics to its small molecule-dominant pipeline.